FLT3 and acute myeloid leukemia: Based on our findings, we propose prioritizing venetoclax-HMA as the first-line salvage therapy for post-transplant AML relapse, particularly in patients with FLT3-ITD mutations or those unsuitable for intensive chemotherapy.